New immunotherapy combo aims to boost kidney cancer surgery success
NCT ID NCT07516366
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot phase II trial tests whether giving two immunotherapy drugs, botensilimab and balstilimab, before surgery is safe and feasible for patients with high-risk clear cell kidney cancer that hasn't spread. Sixteen participants will receive the drugs and then undergo surgery to remove the tumor. The main goals are to see if most patients can complete treatment without major delays and to track side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
botensilimab and balstilimab (immunotherapy drugs)
What this could lead to
If successful, this could show that giving these immunotherapy drugs before surgery is safe and may help shrink kidney tumors, potentially improving outcomes for high-risk patients.
What could go wrong
This is a very small, early-phase trial with only 16 patients. It primarily tests safety and feasibility, not effectiveness. The drugs may cause side effects or not work as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IV RENAL CELL CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.